Allergy Immunotherapy Market, by Treatment Type (Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT)), by Allergy Type (Allergic Rhinitis, Allergic Asthma, Food Allergy, Venom Allergy, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
Immunotherapy is a preventive treatment for allergic reaction to substance such as grass pollens, house dust mites, and bee venom.
Subcutaneous immunotherapy (SCIT) and Sublingual immunotherapy (SLIT) are the immunotherapies used for the treatment of allergic rhinitis, allergic asthma, food allergy, venom allergy, and other allergies.
Subcutaneous immunotherapy (SCIT) is the most commonly used and effective form allergy immunotherapy.
Market Dynamics
The global allergy immunotherapy market is expected to witness significant growth over the forecast period, owing to increasing approval of allergy immunotherapy by regulatory authority.
For instance, in 2017, ALk, a pharmaceutical company focusing on prevention, treatment, and diagnosis of allergy, received the U.S. Food and Drug Administration Biologics License Application (BLA) for its house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet Acarizax.
Furthermore, the tablet is also approved in Europe for the indication of house dust mite (HDM) for adults 18 through 65 years of age under the brand name Acarizax.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook